Polcythemia vera (PV) is a type of myeloproliferative neoplasm (MPN). In PV, the bone marrow overproduces erythrocytes. This results in a range of symptoms, such as itching, burning in the extremities, and an increased risk of thrombosis.
PV cells often have a JAK2 activating mutation, which causes red blood cell proliferation via signaling pathways typically triggered by erythropoietin.
The treatment of PV consists primarily of phlebotomy, which normalizes the blood count and ameliorates the symptoms associated with hypererythrocythemia. Aspirin and chemotherapy may also be used. Targeted agents, such as the JAK2 inhibitor ruxolitinib and immunotherapies like ropeginterferon, are newer developments in the field.